Results in patients with cranial parameningeal sarcoma and metastases (stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols II-IV, 1978-1997: Report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 51, Issue 1, 2008, Pages 17-22

  Raney, Beverly ^a,i,j   Anderson, James ^b   Breneman, John ^c   Donaldson, Sarah S ^d   Huh, Winston ^a   Maurer, Harold ^b   Michalski, Jeff ^e   Qualman, Stephen ^f   Ullrich, Fred ^b   Wharam, Moody ^g   Meyer, William ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

ⁱ DRISCOLL CHILDREN S HOSPITAL   (United States)

^j Driscoll Children's Hospital ^*  (United States)

more..

Author keywords

Childhood adolescent metastatic parameningeal rhabdomyosarcoma; IRSG protocols

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CHILD; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CRANIAL PARAMENINGEAL SARCOMA; DATA BASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MASTOID; METASTASIS; MYELODYSPLASTIC SYNDROME; NOSE CAVITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARANASAL SINUS; PRIMARY TUMOR; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SURVIVAL; TREATMENT FAILURE; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFANT; MALE; NEOPLASM METASTASIS; PROGNOSIS; RHABDOMYOSARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 44149103166     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21492     Document Type: Article

References (22)

1. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-220.
2. Raney RB Jr, Gehan EA, Maurer HM, et al. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (Clinical Groups III and IV). Cancer Clin Trials 1979;2:19-28.
3. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-1922.
4. Crist WM, Raney RB, Ragab A, et al. Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas. Med Pediatr Oncol 1987;15:51-57.
5. Crist W, Gehan EA, Ragab AH, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-630.
6. Ortega JA, Ragab AH, Gehan EA, et al. A feasibility, toxicity, and efficacy study of ifosfamide, actinomycin D, and vincristine for the treatment of childhood rhabdomyosarcoma: A report of the Intergroup Rhabdomyosarcoma Study IV Pilot Study. Am J Pediatr Hematol/Oncol 1993;15:S15-S20.
7. Ruymann FB, Vietti T, Gehan E, et al. Cyclophosphamide dose escalation in combination with vincristine and actinomycin D (VAC) in gross residual sarcoma: A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol/Oncol 1995;17:331-337.
8. Arndt C, Tefft M, Gehan E, et al. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. J Pediatr Hematol/Oncol 1997;19:124-129.
9. Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a Phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001;37:442-448.
10. Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol/Oncol 2001;23:225-233.
11. Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001;19:2091-2102.
12. Donaldson SS, Asmar L, Breneman J, et al. Hyperfractionated radiation in children with rhabdomyosarcoma - Results of an Intergroup Rhabdomyosarcoma Pilot Study. Int J Radiat Oncol Biol Phys 1995;32:903-911.
13. Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 2002;38:22-32.
14. Michalski JM, Meza J, Breneman JC, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004;59:1027-1038.
15. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-V randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma - A report from the IRSG. Int J Radiat Oncol Biol Phys 2001;51:718-728.
16. Kaplan GL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977;35:1-39.
18. Cox DR. Regression models and life tables. J Roy Stat Soc 1972;34:187-220.
19. Newton WA Jr, Soule EH, Hamoudi AB, et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: Clinicopathologic correlation. J Clin Oncol 1988;6:67-75.
20. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas: Pathologic aspects and proposal for a new classification - An Intergroup Rhabdomyosarcoma Study. Cancer 1995;76:1073-1085.
21. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
22. Joshi D, Anderson JR, Paidas C, et al. Age is an independent prognostic factor in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 2004;42:64-73.